Mainz, Germany, May 3, 2012 – TRON scientists will present their latest research at the largest European expert meeting for cancer immunotherapy. The TRON research talks will cover individualized medicine, next-generation sequencing, T-cell functionalities and RNA vaccines. The CIMT Meeting takes place May 23-25th in Mainz, Germany.
Prof. Dr. Ugur Sahin, TRON founder and Executive Director Science and Research, will present progress in individualized medicine as part of the Regulatory Research Session. Dr. John Castle, Head of Computational Medicine and Co-Director of the TRON Biomarker Development Center, is a session speaker on Immunomics. Dr. Tana Omokoko, Head of Immunoreceptors at TRON, will report on research on next-generation sequencing of T-cell receptor repertoires as part of the short talk session. Dr. Mustafa Diken, Co-Director of the TRON Immunotherapy Development Center, will present on the cancer therapeutic potency of naked RNA vaccine. As part of a Satellite workshop, Dr. Holger Hoff, Head of Designer T-Cells will give a talk on T-cell functionality.
The 10th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) takes place in Mainz, Germany, May 23-25, 2012.
TRON presentations at CIMT:
May 23, 17.15 – 19.15
Hall A Late Breakout Session / Immunomics
18:45 – 19:15 John Castle TRON (Mainz, Germany) – Applying next-generation sequencing for immunotherapies
May 24, 10:30 – 12:00
Hall B Short Talk Session II / Improving Immunity
11:45 – 12:00 Mustafa Diken (#079) TRON (Mainz, Germany) – mTOR inhibitor Rapamycin enhances the cancer therapeutic potency of naked RNA vaccine
May 24, 11:00 – 13:30
Hall A Plenary Session 6 / Regulatory Research
11:30 – 11:55 Ugur Sahin TRON (Mainz, Germany) – Exploiting the mutanome for cancer vaccination
May 25, 12:15 – 13:30
Hall B Short Talk Session VI / Personalized Medicine
12:30 – 12.45 Tana Omokoko (#039) TRON (Mainz, Germany) – Next-generation sequencing of γδ T-cell receptor repertoires
May 25, 13:30 – 15:00
Hall C Industry Satellite Symposium II
Holger Hoff TRON (Mainz, Germany) – Targeting inhibitory phosphatases by ectopic expression of miR181a augments T-cell functionality